Switch to:
Also traded in: Germany, Japan

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 1.03
ESALY's Cash to Debt is ranked lower than
57% of the 789 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.69 vs. ESALY: 1.03 )
Ranked among companies with meaningful Cash to Debt only.
ESALY' s Cash to Debt Range Over the Past 10 Years
Min: 0.3  Med: 0.71 Max: N/A
Current: 1.03
Equity to Asset 0.57
ESALY's Equity to Asset is ranked lower than
58% of the 722 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.63 vs. ESALY: 0.57 )
Ranked among companies with meaningful Equity to Asset only.
ESALY' s Equity to Asset Range Over the Past 10 Years
Min: 0.37  Med: 0.44 Max: 0.6
Current: 0.57
0.37
0.6
Interest Coverage 22.97
ESALY's Interest Coverage is ranked lower than
64% of the 629 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 104.15 vs. ESALY: 22.97 )
Ranked among companies with meaningful Interest Coverage only.
ESALY' s Interest Coverage Range Over the Past 10 Years
Min: 5.79  Med: 12.96 Max: 1619.43
Current: 22.97
5.79
1619.43
F-Score: 6
Z-Score: 4.49
M-Score: -2.54
WACC vs ROIC
5.75%
12.73%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 13.36
ESALY's Operating margin (%) is ranked higher than
66% of the 736 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.25 vs. ESALY: 13.36 )
Ranked among companies with meaningful Operating margin (%) only.
ESALY' s Operating margin (%) Range Over the Past 10 Years
Min: 2.42  Med: 11.41 Max: 15.61
Current: 13.36
2.42
15.61
Net-margin (%) 13.24
ESALY's Net-margin (%) is ranked higher than
74% of the 737 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.73 vs. ESALY: 13.24 )
Ranked among companies with meaningful Net-margin (%) only.
ESALY' s Net-margin (%) Range Over the Past 10 Years
Min: -2.32  Med: 8.16 Max: 13.24
Current: 13.24
-2.32
13.24
ROE (%) 12.59
ESALY's ROE (%) is ranked higher than
69% of the 765 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.55 vs. ESALY: 12.59 )
Ranked among companies with meaningful ROE (%) only.
ESALY' s ROE (%) Range Over the Past 10 Years
Min: -3.4  Med: 10.2 Max: 16.4
Current: 12.59
-3.4
16.4
ROA (%) 7.32
ESALY's ROA (%) is ranked higher than
71% of the 797 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.38 vs. ESALY: 7.32 )
Ranked among companies with meaningful ROA (%) only.
ESALY' s ROA (%) Range Over the Past 10 Years
Min: -1.78  Med: 4.56 Max: 9.17
Current: 7.32
-1.78
9.17
ROC (Joel Greenblatt) (%) 35.02
ESALY's ROC (Joel Greenblatt) (%) is ranked higher than
76% of the 786 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 12.88 vs. ESALY: 35.02 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ESALY' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 7.99  Med: 27.9 Max: 56.21
Current: 35.02
7.99
56.21
Revenue Growth (3Y)(%) -1.60
ESALY's Revenue Growth (3Y)(%) is ranked lower than
70% of the 609 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.20 vs. ESALY: -1.60 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
ESALY' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 3.75 Max: 12
Current: -1.6
0
12
EBITDA Growth (3Y)(%) -12.10
ESALY's EBITDA Growth (3Y)(%) is ranked lower than
80% of the 568 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.60 vs. ESALY: -12.10 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
ESALY' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 1.85 Max: 45
Current: -12.1
0
45
EPS Growth (3Y)(%) 4.20
ESALY's EPS Growth (3Y)(%) is ranked lower than
56% of the 534 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.70 vs. ESALY: 4.20 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
ESALY' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -17.3  Med: 6.6 Max: 53.8
Current: 4.2
-17.3
53.8
» ESALY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with ESALY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:OTCPK:SGIOF, NAS:MYL, OTCPK:MKGAY, NYSE:PRGO, OTCPK:MTZPY, OTCPK:ITHUF, OTCPK:APNHY, NYSE:ZTS, NYSE:RDY, OTCPK:SFOSF, OTCPK:HLUYY, NYSE:MNK, NAS:OPK, NYSE:VRX, OTCPK:IPSEY, OTCPK:HYPMY, OTCPK:HKMPF, NYSE:TARO, NAS:NBIX, NYSE:PTHN » details
Traded in other countries:EII.Germany, 4523.Japan,
Eisai Co Ltd is a healthcare company. It is engaged in providing prescription pharmaceuticals, consumer health care products, and diagnostics services.

Eisai Co Ltd was incorporated in Japan on December 6, 1941. It is a pharmaceutical company engaged in manufacturing and marketing of prescription medicines and over-the-counter products. The Company operates in five geographical segments including; Japan Pharmaceutical Business, Americas Pharmaceutical Business, Asia Pharmaceutical Business, EMEA Pharmaceutical Business, and Consumer Healthcare Business - Japan. The Japan Pharmaceutical Business is engaged in the sales of prescription drugs, generic drugs and diagnostics in Japan. The Americas Pharmaceutical Business is engaged in the development and marketing of Oncology-Related Products & Epilepsy Products. The Asia Pharmaceutical Business is engaged in selling Oncology-Related Products, Aricept, Pariet/AcipHex, and Epilepsy Products in Asia including China, South Korea, Taiwan, India and ASEAN nations. The EMEA Pharmaceutical Business sells Epilepsy Products, Oncology-Related Products, Aricept, & Pariet/AcipHex in Europe, the Middle East, Africa, Russia and Oceania. The Consumer Healthcare Business - Japan is engaged in the sale of Chocola BB group of products in Japan.

Ratios

vs
industry
vs
history
P/E(ttm) 26.74
ESALY's P/E(ttm) is ranked higher than
54% of the 537 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 27.49 vs. ESALY: 26.74 )
Ranked among companies with meaningful P/E(ttm) only.
ESALY' s P/E(ttm) Range Over the Past 10 Years
Min: 12.4  Med: 24.6 Max: 119.42
Current: 26.74
12.4
119.42
PE(NRI) 26.74
ESALY's PE(NRI) is ranked higher than
53% of the 538 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 27.46 vs. ESALY: 26.74 )
Ranked among companies with meaningful PE(NRI) only.
ESALY' s PE(NRI) Range Over the Past 10 Years
Min: 12.4  Med: 24.6 Max: 119.43
Current: 26.74
12.4
119.43
Price/Owner Earnings (ttm) 21.74
ESALY's Price/Owner Earnings (ttm) is ranked higher than
69% of the 280 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 32.53 vs. ESALY: 21.74 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
ESALY' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 10.36  Med: 18.34 Max: 32.6
Current: 21.74
10.36
32.6
P/B 3.51
ESALY's P/B is ranked lower than
59% of the 759 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.80 vs. ESALY: 3.51 )
Ranked among companies with meaningful P/B only.
ESALY' s P/B Range Over the Past 10 Years
Min: 1.83  Med: 2.31 Max: 4.2
Current: 3.51
1.83
4.2
P/S 3.54
ESALY's P/S is ranked lower than
56% of the 716 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.85 vs. ESALY: 3.54 )
Ranked among companies with meaningful P/S only.
ESALY' s P/S Range Over the Past 10 Years
Min: 0.96  Med: 1.91 Max: 6.6
Current: 3.54
0.96
6.6
PFCF 28.77
ESALY's PFCF is ranked lower than
60% of the 197 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 19.94 vs. ESALY: 28.77 )
Ranked among companies with meaningful PFCF only.
ESALY' s PFCF Range Over the Past 10 Years
Min: 5.75  Med: 19.69 Max: 206.63
Current: 28.77
5.75
206.63
POCF 24.37
ESALY's POCF is ranked lower than
68% of the 268 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.41 vs. ESALY: 24.37 )
Ranked among companies with meaningful POCF only.
ESALY' s POCF Range Over the Past 10 Years
Min: 4.92  Med: 13.27 Max: 69.65
Current: 24.37
4.92
69.65
EV-to-EBIT 25.82
ESALY's EV-to-EBIT is ranked lower than
61% of the 535 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 21.07 vs. ESALY: 25.82 )
Ranked among companies with meaningful EV-to-EBIT only.
ESALY' s EV-to-EBIT Range Over the Past 10 Years
Min: 9.4  Med: 17 Max: 85.5
Current: 25.82
9.4
85.5
EV-to-EBITDA 18.87
ESALY's EV-to-EBITDA is ranked lower than
54% of the 562 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.70 vs. ESALY: 18.87 )
Ranked among companies with meaningful EV-to-EBITDA only.
ESALY' s EV-to-EBITDA Range Over the Past 10 Years
Min: 6.4  Med: 10.2 Max: 36.7
Current: 18.87
6.4
36.7
Shiller P/E 35.07
ESALY's Shiller P/E is ranked higher than
64% of the 159 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 44.94 vs. ESALY: 35.07 )
Ranked among companies with meaningful Shiller P/E only.
ESALY' s Shiller P/E Range Over the Past 10 Years
Min: 28  Med: 34.1 Max: 39.05
Current: 35.07
28
39.05
Current Ratio 3.11
ESALY's Current Ratio is ranked higher than
63% of the 771 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.31 vs. ESALY: 3.11 )
Ranked among companies with meaningful Current Ratio only.
ESALY' s Current Ratio Range Over the Past 10 Years
Min: 1.85  Med: 2.38 Max: 3.11
Current: 3.11
1.85
3.11
Quick Ratio 2.63
ESALY's Quick Ratio is ranked higher than
65% of the 771 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.75 vs. ESALY: 2.63 )
Ranked among companies with meaningful Quick Ratio only.
ESALY' s Quick Ratio Range Over the Past 10 Years
Min: 1.58  Med: 1.95 Max: 2.63
Current: 2.63
1.58
2.63
Days Inventory 142.94
ESALY's Days Inventory is ranked lower than
63% of the 686 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 114.28 vs. ESALY: 142.94 )
Ranked among companies with meaningful Days Inventory only.
ESALY' s Days Inventory Range Over the Past 10 Years
Min: 142.94  Med: 158.37 Max: 170.66
Current: 142.94
142.94
170.66

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 2.33
ESALY's Dividend Yield is ranked higher than
65% of the 665 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.60 vs. ESALY: 2.33 )
Ranked among companies with meaningful Dividend Yield only.
ESALY' s Dividend Yield Range Over the Past 10 Years
Min: 1.7  Med: 4.09 Max: 6.71
Current: 2.33
1.7
6.71
Dividend Payout 0.58
ESALY's Dividend Payout is ranked lower than
74% of the 386 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.34 vs. ESALY: 0.58 )
Ranked among companies with meaningful Dividend Payout only.
ESALY' s Dividend Payout Range Over the Past 10 Years
Min: 0.58  Med: 1.72 Max: 1000
Current: 0.58
0.58
1000
Forward Dividend Yield 2.25
ESALY's Forward Dividend Yield is ranked higher than
66% of the 646 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.69 vs. ESALY: 2.25 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 2.43
ESALY's Yield on cost (5-Year) is ranked higher than
52% of the 791 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.10 vs. ESALY: 2.43 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
ESALY' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 1.7  Med: 4.09 Max: 6.71
Current: 2.43
1.7
6.71
3-Year Average Share Buyback Ratio -0.10
ESALY's 3-Year Average Share Buyback Ratio is ranked higher than
83% of the 435 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.60 vs. ESALY: -0.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ESALY' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -1.2  Med: 0 Max: 1.3
Current: -0.1
-1.2
1.3

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 37.69
ESALY's Price/Net Current Asset Value is ranked lower than
92% of the 468 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.66 vs. ESALY: 37.69 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
ESALY' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 34.61  Med: 52.67 Max: 244.85
Current: 37.69
34.61
244.85
Price/Tangible Book 6.58
ESALY's Price/Tangible Book is ranked lower than
71% of the 700 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.57 vs. ESALY: 6.58 )
Ranked among companies with meaningful Price/Tangible Book only.
ESALY' s Price/Tangible Book Range Over the Past 10 Years
Min: 4.21  Med: 6.23 Max: 19.26
Current: 6.58
4.21
19.26
Price/Projected FCF 1.93
ESALY's Price/Projected FCF is ranked higher than
61% of the 307 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.77 vs. ESALY: 1.93 )
Ranked among companies with meaningful Price/Projected FCF only.
ESALY' s Price/Projected FCF Range Over the Past 10 Years
Min: 1.05  Med: 1.2 Max: 2.13
Current: 1.93
1.05
2.13
Price/Median PS Value 1.83
ESALY's Price/Median PS Value is ranked lower than
78% of the 615 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.14 vs. ESALY: 1.83 )
Ranked among companies with meaningful Price/Median PS Value only.
ESALY' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.53  Med: 1 Max: 2.97
Current: 1.83
0.53
2.97
Price/Graham Number 2.78
ESALY's Price/Graham Number is ranked lower than
56% of the 438 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.37 vs. ESALY: 2.78 )
Ranked among companies with meaningful Price/Graham Number only.
ESALY' s Price/Graham Number Range Over the Past 10 Years
Min: 1.87  Med: 2.56 Max: 4.61
Current: 2.78
1.87
4.61
Earnings Yield (Greenblatt) (%) 3.84
ESALY's Earnings Yield (Greenblatt) (%) is ranked higher than
57% of the 766 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.00 vs. ESALY: 3.84 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ESALY' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 1.2  Med: 5.9 Max: 10.6
Current: 3.84
1.2
10.6
Forward Rate of Return (Yacktman) (%) -8.88
ESALY's Forward Rate of Return (Yacktman) (%) is ranked lower than
82% of the 344 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.15 vs. ESALY: -8.88 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
ESALY' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -13.6  Med: 1 Max: 22.4
Current: -8.88
-13.6
22.4

More Statistics

Revenue (TTM) (Mil) $4,923
EPS (TTM) $ 2.23
Beta-0.24
Short Percentage of Float0.00%
52-Week Range $53.55 - 67.60
Shares Outstanding (Mil)285.94
» More Articles for ESALY

Headlines

Articles On GuruFocus.com
Vanguard Adds to Eisai Stake Aug 17 2016 

More From Other Websites
Considerable Additional Benefit of Eisai's Halaven® (eribulin) in Advanced Liposarcoma Confirmed by... Dec 04 2016
Halaven® (eribulin) Receives Registration in South Africa for Treatment of Women With Advanced... Nov 30 2016
U.S. FDA Grants Fast Track Designation for the Development of Eisai's Bace Inhibitor E2609 for Early... Nov 17 2016
Eisai Initiates Two Phase III Clinical Studies for Fycompa® (Perampanel) in Young Children With... Nov 07 2016
Eisai Initiates Phase II Study of Dual Orexin Receptor Antagonist Lemborexant in People with... Nov 07 2016
U.K. NICE Recommends Anticancer Agent Halaven as Treatment for Advanced Breast Cancer Nov 04 2016
Eisai Welcomes Positive NICE recommendation for Halaven® (eribulin) for Patients with Locally... Nov 02 2016
Eisai Co., Ltd. :ESALY-US: Earnings Analysis: Q2, 2017 By the Numbers : November 2, 2016 Nov 02 2016
ETF’s with exposure to Eisai Co., Ltd. : October 31, 2016 Oct 31 2016
Enrollment Commences in Phase III Clinical Study of Eisai's BACE Inhibitor E2609 in Early... Oct 31 2016
Eisai to Officially Launch "Chocola BB Rich Ceramide" in Stores Nationwide Oct 13 2016
Preliminary Phase Ib Clinical Study Results for Lenvatinib in Combination with Pembrolizumab in... Oct 12 2016
People with an Advanced Form of Thyroid Cancer Now Able to Benefit From Lenvima® (lenvatinib) in... Oct 09 2016
Exclusive Licensing Agreement for In-house Developed Monoclonal Antibody Farletuzumab in Latin... Oct 04 2016
Eisai: Launch of Uritos Tablets for Overactive Bladder in Thailand Oct 04 2016
BELVIQ XR - a New Once-daily Formulation of BELVIQ for Chronic Weight Management Now Available in... Oct 03 2016
Eisai to Initiate Phase III Clinical Study of Anti-Cancer Agent Lenvatinib as Potential First-Line... Sep 29 2016
Eisai to Present Latest Data on Lenvatinib and Eribulin at ESMO Congress 2016 Sep 28 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)